Avastin loses breast cancer indication

Abstract

US Food and Drug Administration (FDA) Commissioner Margaret Hamburg handed down in November the final decision to revoke approval of Genentech's Avastin (bevacizumab) in metastatic breast cancer. Avastin, which binds to vascular endothelial growth factor, received accelerated approval in 2008 obligating the S. San Francisco–based company to confirm promising data in…